Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Stomach Neoplasms 76Colorectal Neoplasms 28Breast Neoplasms 23Esophageal Neoplasms 20Pancreatic Neoplasms 13Carcinoma, Non-Small-Cell Lung 11Colonic Neoplasms 10Rectal Neoplasms 9Ovarian Neoplasms 8Endometrial Neoplasms 8Neoplasms 7Neoplasm Metastasis 7Gallbladder Neoplasms 7Biliary Tract Neoplasms 7Adenocarcinoma Of Esophagus 7Urinary Bladder Neoplasms 6Uterine Cervical Neoplasms 5Prostatic Neoplasms 5Lung Neoplasms 5HER2-positive Gastric Cancer 5Squamous Cell Carcinoma of Head and Neck 4Cholangiocarcinoma 4Carcinoma, Renal Cell 4Carcinoma, Hepatocellular 4Breast Neoplasms, Male 4Adenocarcinoma 4Thyroid Neoplasms 3Salivary Gland Neoplasms 3Bile Duct Neoplasms 3Vulvar Neoplasms 2

Interventions

Hyperthermic Intraperitoneal Chemotherapy 17Cisplatin 12Oxaliplatin 10Cytoreduction Surgical Procedures 10Fluorouracil 9Paclitaxel 8Mitomycin 8Leucovorin 6Surgical Procedures, Operative 4Doxorubicin 3Observation 2Neoadjuvant Therapy 2Laparoscopy 2Indocyanine Green 2Docetaxel 2Control Groups 2Chemotherapy, Adjuvant 2Carboplatin 2Capecitabine 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2tremelimumab 1sodium thiosulfate 1pembrolizumab 1nilotinib 1lobaplatin 1irinotecan sucrosofate 1genexol-PM 1durvalumab 1dehydroftorafur 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Peritoneal Neoplasms × Trastuzumab × Gastrointestinal × Clear all
NCT01384253 2016-09-30

Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy

Orano Med LLC

Phase 1 Completed
18 enrolled
BreastGastrointestinalGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡